Crizac Q2 FY27 slides: revenue drops 37% but guidance maintained

Crizac’s Q2 FY27 operating income fell 36.7% YoY to ₹1,027 million, while H1 revenue declined 18.3% to ₹3,039 million amid travel disruptions, flight cancellations and currency volatility; applications fell only 3% YoY, which management said points to deferrals rather than cancellations. Management maintained FY27 performance guidance at FY26 levels, expects Q3 revenue growth of 10–12% YoY and a stronger H2, and forecast full-year EBITDA margins of 25–26%. The company reported ₹5,958 million of free cash, declared an interim dividend of ₹4 per share and highlighted market-share gains, including UK study-visa share rising from 3.5% in FY24 to 6.0% in FY26.

Analysis

The key risk is not the weak quarter itself, but the unusually high bar embedded in maintaining FY26 revenue: after a weak H1, the thesis now depends on a sharp H2 recovery and management’s pipeline converting into enrollments and recognized revenue. The stated Q3 growth outlook helps, but does not remove Q4 execution risk; revenue is recognized after course commencement, so visa, travel, or intake slippage can shift revenue across periods rather than merely defer it by weeks.

The near-term market-share gains are strategically valuable, but not yet proof of insulation from UK policy risk: 98.6% of H1 revenue remains tied to one destination market. University financial stress can increase reliance on recruitment partners, while simultaneously increasing counterparty, course-capacity, and commission-pressure risks. The 67.4% revenue exposure to the top ten universities makes those negotiations consequential. Acquisition-led expansion and ancillary services could diversify the model, but the reported destination expansion has yet to displace UK concentration; AI and cross-sell benefits should be treated as unproven until conversion and non-UK revenue improve.

Over the next 1–3 months, the decisive catalyst is Q3 delivery against guidance and evidence that deferred students actually enroll. Over 6–18 months, UK visa rules, university solvency, and execution of acquisitions determine whether share gains compound or concentration risk dominates. The contrarian angle: the market may focus on the headline decline while underweighting share capture, but management’s “one-off” framing may understate recurring policy and destination concentration risks. No clean directional trade is justified without valuation and consensus data.

Key Decisions for Investors

• Treat Crizac as an event-driven watch, not a confirmed recovery long. Reassess after Q3 results: verify year-over-year revenue against the stated 10–12% growth outlook, enrollment conversion, and whether H2 guidance remains intact.
• Use any rally on guidance as an opportunity to test the concentration thesis rather than extrapolate it. Require evidence of rising non-UK revenue and lower top-university concentration before underwriting a structural multiple rerating.
• Monitor UK visa policy, flight disruption, and university intake/capacity announcements as thesis-risk indicators. A renewed deterioration in visa issuance or intake plans would falsify the claim that recent deferrals are mainly temporary.
• Keep acquisition and AI claims out of the base case until reported results show measurable contribution: acquired-market revenue, ancillary-service income, and improved application-to-enrollment conversion. Verify integration costs and cash deployment before assuming the cash balance translates into per-share value.